Journal of Alzheimers Disease & Parkinsonism
Open Access

Richard Mohs

Lilly Corporate Center, Indianapolis, IN, USA

Biography

Richard C. Mohs, Ph.D. is the Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation. He is the author or co-author of over 350 scientific papers, including those describing clinical trials that led to the approval, in the U.S. and other countries, of cholinergic drug treatments for Alzheimer’s disease. In addition to his work for the GAP Foundation, Dr. Mohs serves as a consultant to academic institutions and biopharmaceutical companies. He is the Vice President for Clinical Development at Agenebio, a biotechnology company based in Baltimore. 

Publications

Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases

Alzheimer’s disease (AD) and Parkinson’s disease (PD) pose significant challenges for successful development of new therapies, with anextremely high drug trial failure rate and yet no approved disease modifying drugs available. Given the magnitude of the challenges, it has become clear that larger collaborations and multi-partner joint ... Read More»

Diane Stephenson, Martha Brumfield, Klaus Romero, Janet Woodcock, Issam Zineh, Eric M Reiman, Caroline Tanner, Richard Mohs, Walter Koroshetz, Timothy Nicholas, Lisa J Bain, Derek Hill, Les Shaw, Johan Luthman, Michael Ropacki, Richard Meibach, Peter Loupos, Ken Marek, James Hendrix, Eric Karran, George Vradenburg, Keiju Motohashi, Jesse M Cedarbaum and Mark Forrest Gordon

Conference Proceeding: J Alzheimers Dis Parkinsonism 2015, 5:183

DOI: 10.4172/2161-0460.1000183

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article